Common Stock
| Exchange | |
|---|---|
| Price | |
| Change (%) | |
| Volume | |
| Data as of Oct 17, 2024 11:30 PM EDT | |
Minimum 15 minutes delayed. Source:
Investors & Media
Aceragen is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Our portfolio includes late-stage programs that we are developing to be innovative therapeutics capable of addressing the unmet medical needs of those individuals.